Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
Novo Nordisk's new GLP1 Receptor Agonist Amycretin recently completed phase 2 trials and delivered fantastic results:
News Details
The results are pretty amazing:
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively.
On a dose of 5mg after 28 weeks (just 6 months), 16% body weight loss is nothing short of amazing.
Amycretin isn't the only new GLP1 on the market though – let's dive in and see how it compares to other formulations under development.
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis of Amycretin's results, check us out on Substack:
